GP方案治疗三阴性晚期乳腺癌的临床观察

目的观察吉西他滨联合顺铂(GP)方案治疗ER、PR、HER-2均阴性的晚期转移性乳腺癌的疗效及不良反应。方法以GP方案治疗经免疫组化证实ER、PR、HER-2均阴性,对蒽环或紫杉类耐药的晚期转移性乳腺癌患者46例,以吉西他滨1000 mg/m2静脉滴注,第1,8天;顺铂25 mg/m2静脉滴注,第1～3天。21 d为1个周期,至少2个周期,2个周期后评价疗效和毒副反应。结果 46例患者均可评价疗效,其中获完全缓解(CR)2例(4.4%),部分缓解(PR)15例(32.6%),稳定(SD)19例(41.3%),进展(PD)10例(21.7%),总有效率(CR+PR)为37.0%;中位疾病进展时间为5.3个月。主要不良反应包括骨髓抑制和胃肠道反应,无化疗相关死亡。结论 GP方案对蒽环类或紫杉类耐药的三阴性晚期乳腺癌有较好的近期疗效,毒副反应可耐受,是有效的解救方案之一。

Effect of Gemcitabine and Cisplatin Combination Chemotherapy for Advanced Triple-Negative Breast Cancer

Objective To observe the efficacy and toxicities of combination chemotherapy with gemcitabine and cisplatin on triple-negative(estrogen receptor,progesterone receptor and human epidermal growth factor receptor 2 were all negative) metastatic breast cancer.Methods Forty-six patients with anthracycline-resistant triple-negative metastatic breast cancer confirmed by immunohistochemical tests were given gemcitabine 1000 mg/m2 on d1 and d8,and DDP 25 mg/m2 on d1,d2 and d3.Treatments were repeated every 21 days and all patients received at least two cycles.The efficacy and toxicities were evaluated two cycles after treatment.Results Among these 46 patients,the overall response rate was 37.0% with 2 CR,15 PR,19 SD,10 PD.The median TTP(time to progression) was 5.3 months,no patients died in correlated with the GP regimen.The main toxicities were myelosuppression and gastrointestinal tract reaction.Conclusion The combination of gemcitabine and cisplatin for anthracycline-resistant or taxanes-resistant triple-negative metastatic breast cancer was a effective regime with tolerable toxicities.